Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue From Contracts With Customers (Tables)

v3.22.1
Note 3 - Revenue From Contracts With Customers (Tables)
3 Months Ended
Mar. 31, 2022
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Three Months Ended

March 31,

 
   

2022

   

2021

 

License revenue:

               

Tc99m tilmanocept - Europe

  $     $ 22,486  
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
   

Three Months Ended March 31,

 
   

2022

   

2021

 

Total deferred revenue, beginning of period

  $ 700,000     $ 700,000  

Deferred revenue related to milestones achieved

    100,000        

Total deferred revenue, end of period

  $ 800,000     $ 700,000